drugset
drugset / Trial / NCT04342975

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975 ↗

Phase 2 Completed 54 enrolled Mayo Clinic Elysium Health · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.

Timeline

Start
2020-12-01
Primary completion
2024-03-14
Completion
2024-03-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicotinamide riboside Small molecule 1000 mg Oral
Comparator Pterostilbene Small molecule 200 mg Oral

Indications

acute kidney injury